bluuebunny/crossref_metadata_2025_split huggingface dataset:
ChemInform Abstract: Thermal Solvent‐Free Synthesis of Novel Pyrazolyl Chalcones and Pyrazolines as Potential Antimicrobial Agents.
Authors: Siddiqui Zeba N. , Musthafa T. N. Mohammed , Ahmad Anis , Khan Asad U. 
Published: September 2011

AbstractSimple thermal heating under neat conditions gives access to new chalcones (III) which are then converted to the corresponding pyrazolines (IV) in a solvent‐free reaction.
ChemInform Abstract: Microwave‐Assisted Synthesis, Crystal Structure of Pyrazolo[1,5‐a]pyrazin‐4(5H)‐ones and Their Selective Effects on Lung Cancer Cells.
Authors: Liu Ning , Zhang Jin‐Hua , Zhao Bao‐Xiang , Zhao Jing , Su Le , Dong Wen‐Liang , Zhang Shang‐Li , Miao JunYing 
Published: September 2011

AbstractA facile microwave‐assisted route to pyrazolopyrazinones (III) (12 examples) is given.
ChemInform Abstract: Zn[(L)proline]2 in Water: A New Easily Accessible and Recyclable Catalytic System for the Synthesis of Pyrazoles.
Authors: Kidwai Mazaahir , Jain Arti , Poddar Roona 
Published: September 2011

AbstractA variety of pyrazoles and diazepines is prepared from 1,3‐dicarbonyl compounds and hydrazine, hydrazides, ortho‐phenylenediamine and 4,5‐diaminophthalonitrile.
ChemInform Abstract: A Facile Method to Construct Cyclic α,α‐Difluoromethylenephosphonate — A Novel Cyclic Phosphate Mimic.
Authors: Lin Yun , Liu Jin‐Tao 
Published: September 2011

AbstractCyclic α,α‐difluoromethylenephosphonates of type (II) and (V) are prepared by halogen‐induced intramolecular cyclization of (I) or (IV).
ChemInform Abstract: Synthesis of Aryl(ferrocenyl)methanols via an Enantioselective Addition of Arylboronic Acids.
Authors: Tisovsky Pavol , Meciarova Maria , Sebesta Radovan 
Published: September 2011

AbstractThe reaction proceeds via microwave‐assisted formation of zinc reagents and is catalyzed by ferrocenyl oxazolinyl alcohol.
ChemInform Abstract: Synthesis and Antitumor Activity of Ring A‐Modified Glycyrrhetinic Acid Derivatives.
Authors: Csuk Rene , Schwarz Stefan , Siewert Bianka , Kluge Ralph , Stroehl Dieter 
Published: September 2011

AbstractA series of derivatives of glycyrrhetinic acid (Ia) with altered lipophilicity in ring A are prepared and their apoptotic activities are discussed.
ChemInform Abstract: Antifibrotic Constituents of Alnus firma on Hepatic Stellate Cells.
Authors: Lee Mina , Lee Mi Kyeong , Kim Young Choong , Sung Sang Hyun 
Published: September 2011

AbstractBioactivity‐guided fractionation leads to the isolation of a new triterpenoid characterized as lup‐20(29)en‐2,28‐diol‐3‐yl caffeate (I) together with 12 known diarylheptanoids.
ChemInform Abstract: In vitro and in vivo Anticancer Activity Evaluation of Ursolic Acid Derivatives.
Authors: Shao Jing‐Wei , Dai Yong‐Chao , Xue Jin‐Ping , Wang Ji‐Chuang , Lin Feng‐Ping , Guo Yang‐Hao 
Published: September 2011

AbstractTwentythree ursolic acid derivatives including ten novel compounds are synthesized by modification of the C‐3 and C‐28 positions.
ChemInform Abstract: Cytotoxic and PPARs Transcriptional Activities of Sterols from the Vietnamese Soft Coral Lobophytum laevigatum.
Authors: Kim Young Ho , et al. et al. 
Published: September 2011

AbstractA new unusual sterol, named lobophytosterol (I), and five known metabolites are isolated from the methanol extract of the soft coral Lobophytum laevigatum.
ChemInform Abstract: Penicisteroids A and B, Antifungal and Cytotoxic Polyoxygenated Steroids from the Marine Alga‐Derived Endophytic Fungus Penicillium chrysogenum QEN‐24S.
Authors: Gao Shu‐Shan , Li Xiao‐Ming , Li Chun‐Shun , Proksch Peter , Wang Bin‐Gui 
Published: September 2011

AbstractTwo new polyoxygenated steroids, named penicisteroids A (I) and B (II), are obtained from the culture extract of Penicillium chrysogenum QEN‐24S, an endophytic fungus isolated from an unidentified marine red algal species.
ChemInform Abstract: Biological Evaluation of 3′‐O‐Alkylated Analogues of Salacinol, the Role of Hydrophobic Alkyl Group at 3′ Position in the Side Chain on the α‐Glucosidase Inhibitory Activity.
Authors: Tanabe Genzoh , Otani Tetsu , Cong Wenying , Minematsu Toshie , Ninomiya Kiyofumi , Yoshikawa Masayuki , Muraoka Osamu 
Published: September 2011

AbstractFour hydrophobically modified analogues (I) of the naturally occurring α‐glucosidase inhibitor salacinol are prepared and evaluated for their inhibitory activity.
ChemInform Abstract: Synthesis of Substituted Indolizino[8,7‐b]indoles from Harmine and Their Biological Activity.
Authors: Nurmaganbetov Zh. S. , Shultz E. E. , Chernov S. V. , Turmukhambetov A. Zh. , Seydakhmetova R. B. , Shakirov M. M. , Tolstikov G. A. , Adekenov S. M. 
Published: September 2011

AbstractTitle compounds [(VI), (VIII), and (X)] are synthesized starting from harmine (I) via quaternized derivatives (V).
ChemInform Abstract: Asymmetric Synthesis of Stagonolide‐D and Stagonolide‐G.
Authors: Mahapatra Tridib , Das Tapas , Nanda Samik 
Published: September 2011

AbstractStagonolide‐D (VII) is obtained via HWE‐olefination of aldehyde (I), selective reduction of ester (III), Sharpless asymmetric epoxidation of alkene (IV), and ring‐closing metathesis of diene (VI) as key steps.
ChemInform Abstract: Synthesis and Biological Evaluation of 4‐Nitro‐Substituted 1,3‐Diaryltriazenes as a Novel Class of Potent Antitumor Agents.
Authors: Osmak Maja , et al. et al. 
Published: September 2011

Abstractp‐Nitro‐substituted 1,3‐diaryltriazenes with two additional electron‐withdrawing groups at their ortho position are highly cytotoxic.
Review on Portable Energy Systems: From Electrochemical Systems to Energy Harvesting
Authors: Krewer Ulrike 
Published: September 2011

AbstractPortable Energiesysteme stellen ortsunabhängig elektrische Energie zur Verfügung. Eingesetzt werden bisher hauptsächlich elektrochemische Energiespeicher, üblicherweise Batterien. Diese sind jedoch nur bedingt für netzferne Anwendungen mit höherer Laufzeit oder höherem Energiebedarf geeignet; hier werden Energiewandler wie Brennstoffzellen, Mikroturbinen und Energy‐Harvesting‐Technologien eingesetzt. Dieser Übersichtsartikel stellt alle Technologien aus verfahrenstechnischer Sicht dar, vergleicht die Technologien und gibt Einblicke in den Stand der Forschung und zukünftige Herausforderungen.
Reduction of Hydrocarbon Emissions in Solar Cell Fabrication – A Life Cylce Assessment
Authors: Hottenroth Heidi , Schottler Martin , Schmidt Mario 
Published: September 2011

AbstractMit Hilfe einer Ökobilanz werden verschiedene technologische Varianten zur Minderung von Kohlenwasserstoffemissionen bei der Solarzellenfertigung untersucht. Hierbei verursachen die Verbrennungsverfahren deutlich mehr potenzielle Umweltwirkungen als die Kondensation oder der Biofilter. Beim Vergleich der Minderungstechnologien mit der direkten Abgabe der unbehandelten Abluft an die Umbebung zeigt sich, dass durch die untersuchten Behandlungsverfahren die beabsichtigte Verminderung von Gesundheitsbelastungen überkompensiert wird. Das Ziel der Richtlinie zur integrierten Vermeidung und Verminderung von Umweltverschmutzung – den Schutz der Umwelt insgesamt zu gewährleisten – wird somit durch diese Verfahren nicht erfüllt.
The permeability of wood‐chip beds: The effect of compressibility
Authors: Alaqqad M. , Bennington C. P. J. , Martinez D. M. 
Published: September 2011

AbstractIn this work, we present a methodology to characterise the permeability of a compressible bed of wood chips under mechanical load. We show that under the limiting condition of when the mechanical compression is large in comparison to hydraulic pressure the equations of motion can be linearised and solved to produce an expression approximating the variation in porosity along the length of the bed. We show how this may be used, in conjunction with multiple linear regression to estimate permeability of the bed. In the experimental portion of the work we measure the permeability of a bed of hemlock wood chips at three different kappa numbers κ, and compacted to three different mechanical loads, i.e. compaction pressures pc. The usefulness of these estimates was then tested by predicting the pressure drop versus flow relationship for conditions outside the range of the linearised solution; the equations of motion were solved numerically with knowledge of the measured permeability. Good agreement was obtained. After accounting for compressibility effects, we find that our correlation has lower flow resistances than the literature correlations. © 2011 Canadian Society for Chemical Engineering
Synthesis of New 2‐Phenylpyrano[3,2‐b]phenothiazin‐4(6H)‐one Derivatives
Authors: Bansode Tanaji N. , Meshram Gangadhar A. 
Published: September 2011

AbstractA new synthesis of 2‐phenylpyrano[3,2‐b]phenothiazin‐4(6H)‐one derivatives was reported. First 2,10‐diacetyl‐3‐hydroxyphenothiazine (2) was converted into their benzoyloxy esters (3a–3j) using different aromatic carboxylic acids in the presence of phosphorous oxychloride in pyridine. Benzoyloxy esters were converted into their 1,3‐diones (4a–4j) by using dry KOH in pyridine via Baker‐Venkataraman transformation reaction. The 1,3‐diones thus obtained were cyclised to pyranophenothiazines (5a–5j) by refluxing in an acetic acid/HCl mixture.
Acquired Long QT Interval: A Case Series of Multifactorial QT Prolongation
Authors: Digby Geneviève C. , Pérez Riera Andrés Ricardo , Barbosa Barros Raimundo , Simpson Christopher S. , Redfearn Damian P. , Methot Michelle , Femenía Francisco , Baranchuk Adrian 
Published: September 2011

AbstractBackground:Acquired long QT (LQT) interval is thought to be a consequence of drug therapy and electrolyte disturbances.Hypothesis:We characterize the potential effects of polypharmacy in a case series of acquired LQT and torsades de pointes (TdP) in order to determine whether multiple risk factors play a role in the development of LQT.Methods:The case series consisted of 11 patients presenting to 4 tertiary care hospitals with LQT and ≥2 risk factors for developing LQT. Clinical characteristics, medications, electrolyte disturbances, and course in hospital were analyzed.Results:Mean age was 49.1 ± 5.8 years. Eight patients were female. Four had hypertension, 1 had a history of dilated cardiomyopathy, and 1 patient demonstrated complete atrioventricular block. Average QTc interval at presentation was 633.8 ± 29.2 ms. Nine patients developed TdP. In 3, LQT was not initially detected and amiodarone was administered, followed by development of TdP. Patients were taking an average of 2.8 ± 0.3 QT‐prolonging medications—an antidepressant in 6 cases and a diuretic in 8 cases. All patients had an electrolyte abnormality; 8 patients presented with severe hypokalemia (<3.0 mmol/L). Average serum potassium and magnesium were 2.82 ± 0.10 mmol/L and 0.75 ± 0.03 mmol/L, respectively. There were no deaths.Conclusions:This case series highlights the risks of polypharmacy in the development of LQT and TdP. It illustrates the importance of early detection of LQT in patients with multiple risk factors in ensuring appropriate treatment. © 2011 Wiley Periodicals, Inc.The authors have no funding, financial relationships, or conflicts of interest to disclose.
Structure–Activity Relationship for the First‐in‐Class Clinical Steroid Sulfatase Inhibitor Irosustat (STX64, BN83495)
Authors: Woo L. W. Lawrence , Ganeshapillai Dharshini , Thomas Mark P. , Sutcliffe Oliver B. , Malini Bindu , Mahon Mary F. , Purohit Atul , Potter Barry V. L. 
Published: September 2011

AbstractStructure–activity relationship studies were conducted on Irosustat (STX64, BN83495), the first steroid sulfatase (STS) inhibitor to enter diverse clinical trials for patients with advanced hormone‐dependent cancer. The size of its aliphatic ring was expanded; its sulfamate group was N,N‐dimethylated, relocated to another position and flanked by an adjacent methoxy group; and series of quinolin‐2(1H)‐one and quinoline derivatives of Irosustat were explored. The STS inhibitory activities of the synthesised compounds were assessed in a preparation of JEG‐3 cells. Stepwise enlargement of the aliphatic ring from 7 to 11 members increases potency, although a further increase in ring size is detrimental. The best STS inhibitors in vitro had IC50 values between 0.015 and 0.025 nM. Other modifications made to Irosustat were found to either abolish or significantly weaken its activity. An azomethine adduct of Irosustat with N,N‐dimethylformamide (DMF) was isolated, and crystal structures of Irosustat and this adduct were determined. Docking studies were conducted to explore the potential interactions between compounds and the active site of STS, and suggest a sulfamoyl group transfer to formylglycine 75 during the inactivation mechanism.
N‐[2‐Methyl‐5‐(triazol‐1‐yl)phenyl]pyrimidin‐2‐amine as a Scaffold for the Synthesis of Inhibitors of Bcr‐Abl
Authors: Arioli Federica , Borrelli Stella , Colombo Francesco , Falchi Federico , Filippi Irene , Crespan Emmanuele , Naldini Antonella , Scalia Giusy , Silvani Alessandra , Maga Giovanni , Carraro Fabio , Botta Maurizio , Passarella Daniele 
Published: September 2011

AbstractN‐[2‐Methyl‐5‐(triazol‐1‐yl)phenyl]pyrimidin‐2‐amine derivatives were synthesized and evaluated in vitro for their potential use as inhibitors of Bcr‐Abl. The design is based on the bioisosterism between the 1,2,3‐triazole ring and the amide group. The synthesis involves a copper(I)‐catalyzed azide–alkyne cycloaddition (CuAAC) as the key step, with the exclusive production of anti‐(1,4)‐triazole derivatives. One of the compounds obtained shows general activity similar to that of imatinib; in particular, it was observed to be more effective in decreasing the fundamental function of cdc25A phosphatases in the K‐562 cell line.
The impact of July hospital admission on outcome after surgery for spinal metastases at academic medical centers in the United States, 2005 to 2008
Authors: Dasenbrock Hormuzdiyar H. , Clarke Michelle J. , Thompson Richard E. , Gokaslan Ziya L. , Bydon Ali 
Published: September 2011

AbstractBACKGROUND:Despite widespread belief that patients admitted to teaching hospitals in July—the beginning of the academic year—have inferior outcomes, there has been little evidence to support the existence of the July phenomenon. Moreover, the impact of July admission on the outcomes after surgery for spinal metastases has not been investigated.METHODS:Data from the Nationwide Inpatient Sample (2005‐2008) were retrospectively extracted. Patients who underwent surgery for metastatic spinal disease and were admitted to a teaching hospital were included. Multivariate logistic regression was conducted to calculate the odds of in‐hospital death, the occurrence of an intraoperative complication, and the development of a postoperative complication depending on whether admission was in July or between August and June. All analyses were adjusted for differences in patient age, sex, comorbidities, primary tumor histology, visceral metastases, myelopathy, insurance status, hospital volume, and admission type.RESULTS:A total of 2920 admissions were evaluated. In‐hospital mortality was higher in July compared with between August and June—7.5% versus 4.2%. The adjusted odds of in‐hospital death were significantly higher for patients admitted in July (odds ratio [OR], 1.81; 95% confidence interval [CI], 1.13‐2.91; P = .01). Patients admitted in July were significantly more likely to develop an intraoperative complication (OR, 2.11; 95% CI, 1.41‐3.17; P < .001), but not a postoperative complication (OR, 1.08; 95% CI, 0.81‐1.45; P = .60).CONCLUSIONS:In this nationwide study based on an administrative database, patients undergoing surgery for metastatic spinal disease at teaching hospitals in July had higher rates of in‐hospital mortality and intraoperative complications. Cancer 2012;. © 2011 American Cancer Society.
Randomized controlled trial of acitretin versus placebo in patients at high‐risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)
Authors: Kadakia Kunal C. , Barton Debra L. , Loprinzi Charles L. , Sloan Jeff A. , Otley Clark C. , Diekmann Brent B. , Novotny Paul J. , Alberts Steven R. , Limburg Paul J. , Pittelkow Mark R. 
Published: September 2011

AbstractBACKGROUND:Chemoprevention with systemic retinoids has demonstrated promise in decreasing the incidence of new primary nonmelanoma skin cancers (NMSCs) in immunocompromised post‐transplantation recipients. There is limited evidence for the use of systemic retinoids in the nontransplantation patient. To the authors' knowledge, this is the first randomized controlled trial to assess the efficacy of acitretin as a chemopreventive agent in nontransplantation patients at high‐risk for NMSC.METHODS:The study was designed as a prospective, randomized, double‐blind, placebo‐controlled clinical trial. To test the possible skin cancer‐preventing effect of a 2‐year treatment with acitretin, 70 nontransplantation patients aged ≥18 years who had a history of ≥2 NMSCs within 5 years of trial onset were randomized to receive either placebo or acitretin 25 mg orally 5 days per week. The primary outcome measure was the rate of new NMSC development.RESULTS:Seventy patients were randomized to receive either acitretin alone (N = 35) or placebo (N = 35). During the 2‐year treatment period, the patients who received acitretin did not have a statistically significant reduction in the rate of new primary NMSCs (odds ratio, 0.41; 95% confidence interval, 0.15‐1.13; 54% vs 74%; P = .13). However, using the incidence of new NMSC, the time to new NMSC, and total NMSC counts, an umbrella test indicated a significant trend that favored the use of acitretin (chi‐square statistic, 3.94; P = .047). The patients who received acitretin reported significantly more mucositis and skin toxicities compared with the patients who received placebo.CONCLUSIONS:Although there was not a statistically significant benefit observed with the use of acitretin, this may have been the result of low statistical power. Cancer 2012;. © 2011 American Cancer Society.
Prognostic value of MYC rearrangement in cases of B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma
Authors: Lin Pei , Dickason Timothy J. , Fayad Luis E. , Lennon Patrick A. , Hu Peter , Garcia Mar , Routbort Mark J. , Miranda Roberto , Wang Xumei , Qiao Wei , Medeiros L. Jeffrey 
Published: September 2011

AbstractBACKGROUND:B‐cell lymphoma, Unclassifiable with features intermediate between diffuse large B‐cell lymphoma (DLBCL) and Burkitt lymphoma, for convenience referred to here as unclassifiable B‐cell lymphoma, is a category in the 2008 World Health Organization system used for a group of histologically aggressive neoplasms that are difficult to classify definitively. Currently, there is no established standard therapy for these neoplasms.METHODS:The authors assessed MYC status and correlated it with treatment response and outcome in a group of 52 patients with unclassifiable B‐cell lymphoma treated with either a standard DLBCL regimen (R‐CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone‐related therapy]) or more intensive regimens, such as R‐hyper‐CVAD (rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high‐dose methotrexate and cytarabine). The regimens were selected by the treating clinicians based on the overall clinical and pathological findings.RESULTS:Thirty (58%) unclassifiable B‐cell lymphomas had MYC abnormalities (MYC+) including 27 with rearrangement, 2 with amplification, and 1 with both. The MYC+ and MYC− groups were similar in their age distribution and International Prognostic Index scores. Progression‐free survival of patients with MYC+ unclassifiable B‐cell lymphoma treated initially with R‐CHOP was significantly worse than patients treated with R‐hyper‐CVAD (P = .0358). In contrast, for the MYC− unclassifiable B‐cell lymphoma group, some patients responded to R‐CHOP, and others were refractory to R‐hyper‐CVAD.CONCLUSIONS:MYC aberrations are common in unclassifiable B‐cell lymphoma. The presence of MYC aberrations identifies a patient subset that requires more aggressive therapy than R‐CHOP. In contrast, MYC− unclassifiable B‐cell lymphoma patients responded variably to either R‐CHOP or aggressive therapy, and the latter showed no survival advantage. Cancer 2011;. © 2011 American Cancer Society.
Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers
Authors: Azad Abul Kalam , Bairati Isabelle , Samson Elodie , Cheng Dangxiao , Cheng Lu , Mirshams Maryam , Savas Sevtap , Waldron John , Wang Changshu , Goldstein David , Xu Wei , Meyer Francois , Liu Geoffrey 
Published: September 2011

AbstractBACKGROUND:Secondary primary cancers (SPCs), a major cause of morbidity and mortality in head and neck cancers (HNCs), are commonly associated with field cancerization. We comprehensively evaluated 23 germline sequence variants (from published literature) in 17 genes from 7 biological pathways associated with the HNC survival. Because cancer prognosis correlates with disease aggressiveness, the factors that determine aggressive disease may influence field cancerization process to favor SPC development. We thus hypothesized that the same sequence variants associated with HNC survival can also be associated with SPC.METHODS:Germline DNA from 531 stage I‐II radiation‐treated HNC patients (originally recruited for an alpha‐tocopherol/beta‐carotene placebo‐controlled secondary prevention clinical trial) were genotyped, and analyzed using Cox proportional hazards models, stratified by treatment arm, adjusting for clinical prognostic factors.RESULTS:The majority of SPCs were of lung and HNCs. Median follow‐up time was 5 years. SPCs were diagnosed in 21% of patients. The 5‐year SPC‐free survival was 79%. All but 1 evaluated sequence variant were not associated with SPC. There was a strong association of the DNA (cytosine‐5‐)‐methyltransferase 3 beta (DNMT3B) sequence variant, DNMT3B:C149T (rs2424913) with SPC: the adjusted hazard ratio (aHR) for TT versus CC was 2.23 (1.32‐3.78; P = .003), whereas each variant T allele was associated with an aHR of 1.49 (1.15‐1.95; P = .003).CONCLUSIONS:A functional sequence variant in DNMT3B is associated with the development of SPCs in HNC early stage patients treated with radiation. Aberrant DNA methylation may be an important modulator of SPC development in at‐risk individuals with HNCs. Cancer 2011;. © 2011 American Cancer Society.